PLIANT director granted 70,000 PLRX stock options

PLIANT THERAPEUTICS, INC. director Darren S. Cline received a grant of stock options covering 70,000 shares of common stock.

Rhea-AI Filing Summary

PLIANT THERAPEUTICS, INC. director Darren S. Cline received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036.

These options were granted as compensation rather than bought in the open market. According to the vesting schedule, 25% of the options vest and become exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds options for 70,000 shares directly.

Insider Trade Summary

Grant/Award: 70,000 shares

Grant/Award 1 txn

Insider Cline Darren S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 70,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Key Figures

Option grant size: 70,000 shares Exercise price: $1.14 per share Shares after grant: 70,000 options +4 more

7 metrics

Option grant size 70,000 shares Stock Option (Right to Buy) underlying common stock

Exercise price $1.14 per share Conversion or exercise price of stock option

Shares after grant 70,000 options Total derivative securities following transaction

Option expiration June 11, 2036 Expiration date of stock option award

First vesting date October 1, 2026 25% of option shares vest and become exercisable

Second vesting date January 1, 2027 Additional 25% of option shares vest

Third vesting date April 1, 2027 Additional 25% of option shares vest

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"25% of the shares subject to such option vest and become exercisable"

annual meeting of stockholders financial

"the earlier of the one-year anniversary ... or (ii) the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the PLRX Form 4 report for director Darren S. Cline?

The Form 4 reports that director Darren S. Cline received stock options for 70,000 PLRX common shares. These options are a compensation grant, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.

How many PLRX shares are covered by Darren Cline’s new stock option grant?

The new stock option grant covers 70,000 shares of PLIANT THERAPEUTICS common stock. All 70,000 shares are tied to a single option award that vests over time, giving him potential future equity exposure if the options are exercised.

What is the exercise price on Darren Cline’s PLRX stock options?

The stock options granted to Darren Cline have an exercise price of $1.14 per share. This means he can later buy PLRX common shares at $1.14, once the options vest and before they expire, if he chooses to exercise them.

When do Darren Cline’s PLRX stock options vest according to the Form 4?

The options vest in four equal 25% installments: on October 1, 2026, January 1, 2027, and April 1, 2027, with the final 25% vesting on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continued board service.

When do Darren Cline’s PLRX stock options expire?

The stock options granted to Darren Cline expire on June 11, 2036. He must exercise vested options on or before that expiration date; otherwise, any unexercised portion will lapse and can no longer be converted into PLRX common shares.

Is Darren Cline buying or selling PLRX stock in this Form 4 filing?

The Form 4 shows an option grant, not a stock purchase or sale. Darren Cline acquired 70,000 stock options as a compensation award, giving him the right to buy PLRX shares later, rather than transacting in the public market now.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Darren S

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	06/11/2026		A		70,000		(1)	06/11/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)